N. Carriglio

Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.

E. Draghici, A. Aiuti, P. Cristofori, 2017, Human gene therapy. Clinical development.

Autoimmune Dysregulation and Purine Metabolism in Adenosine Deaminase Deficiency

A. Aiuti, I. Brigida, N. Carriglio, 2012, Front. Immun..

Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.

M. Roncarolo, P. L. Poliani, F. Sanvito, 2012, Blood.

Progress in gene therapy for primary immunodeficiencies using lentiviral vectors

A. Aiuti, N. Carriglio, A. V. Sauer, 2014, Current opinion in allergy and clinical immunology.

Hematopoietic Tumors in a Mouse Model of X-linked Chronic Granulomatous Disease after Lentiviral Vector-Mediated Gene Therapy

P. Rancoita, C. Di Serio, L. Naldini, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients

A. Bertuzzi, M. Rescigno, C. Carlo-Stella, 2022, Life Science Alliance.

A booster dose of mRNA-based COVID-19 vaccines fosters the development of an immune response in immunosuppressed fragile patients.

A. Bertuzzi, M. Rescigno, C. Selmi, 2022, medRxiv.

Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients

L. Leocani, G. Comi, C. Baldoli, 2017, Scientific Reports.